483
Grifols Therapeutics LLCGrifols Therapeutics LLC – FDA 483, Feb 5, 2026
Record Details
Grifols Therapeutics LLC in Clayton, NC, a plasma derivatives facility, was cited for significant quality control issues during an FDA inspection. Observations included a failure to thoroughly investigate recurring discrepancies like IGM excursions and missing sample results, as well as a failure to report serious adverse events within the required 15-day timeframe. Additionally, the firm did not adhere to its own written production and process control procedures for product rework.
View Company Profile
ID · f00000c6-d7fa-4773-9efc-0d7051024010
Other documents for Grifols Therapeutics LLC
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.